{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:41:12Z","timestamp":1789872072150,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL139425"],"award-info":[{"award-number":["T32 HL139425"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["946222"],"award-info":[{"award-number":["946222"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ajpc.2025.100978","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:09:12Z","timestamp":1743484152000},"page":"100978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology"],"prefix":"10.1016","volume":"22","author":[{"given":"Seyedmohammad","family":"Saadatagah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Larouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Naderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftikhar J.","family":"Kullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin D.","family":"Michos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajpc.2025.100978_bib0001","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00041433-200104000-00008","article-title":"Very-low-density lipoprotein assembly and secretion","volume":"12","author":"Shelness","year":"2001","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ajpc.2025.100978_bib0002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol"},{"issue":"8","key":"10.1016\/j.ajpc.2025.100978_bib0003","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100978_bib0004","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3 Pt 1","key":"10.1016\/j.ajpc.2025.100978_bib0005","article-title":"Regulation of fatty acid movement in human adipose tissue in the postabsorptive-to-postprandial transition","volume":"266","author":"Frayn","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ajpc.2025.100978_bib0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cca.2016.02.004","article-title":"Chylomicrons: advances in biology, pathology, laboratory testing, and therapeutics","volume":"455","author":"Julve","year":"2016","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100978_bib0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12944-017-0511-9","article-title":"Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics","volume":"16","author":"Retterst\u00f8l","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100978_bib0008","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacl.2023.09.002","article-title":"Severe hypertriglyceridemia prevalence at a primary care setting in Catalonia, Spain","volume":"17","author":"Ortega","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2025.100978_bib0009","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12944-020-01302-x","article-title":"The burden of familial chylomicronemia syndrome in Canadian patients","volume":"19","author":"Gaudet","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"11","key":"10.1016\/j.ajpc.2025.100978_bib0010","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1161\/ATVBAHA.124.320955","article-title":"Ethnic diversity and distinctive features of familial versus multifactorial chylomicronemia syndrome: insights from the UK FCS National Registry","volume":"44","author":"Bashir","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpc.2025.100978_bib0011","doi-asserted-by":"crossref","unstructured":"Saadatagah S, Naderian M, Larouche M, Gaudet D, Kullo IJ, Ballantyne CM Epidemiology and longitudinal course of chylomicronemia: insights from NHANES and a large health care system. J Clin Lipidol. 2025 In press. doi:10.1016\/j.jacl.2025.02.008.","DOI":"10.1016\/j.jacl.2025.04.009"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100978_bib0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MED.0000000000000903","article-title":"An overview of persistent chylomicronemia: much more than meets the eye","volume":"32","author":"Larouche","year":"2025","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ajpc.2025.100978_bib0013","unstructured":"Javed F, Garg A, Patni, Nivedita, Gaudet D, Hegele RA, Ahmad Z. Familial chylomicronemia syndrome: expert opinion. J Clin Lipidol. In press, 2025."},{"key":"10.1016\/j.ajpc.2025.100978_bib0014","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia","volume":"283","author":"Paquette","year":"2019","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100978_bib0015","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100978_bib0016","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2013current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.ajpc.2025.100978_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11883-020-00885-1","article-title":"Familial chylomicronemia syndrome (FCS): recent data on diagnosis and treatment","volume":"22","author":"Gallo","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ajpc.2025.100978_bib0018","doi-asserted-by":"crossref","unstructured":"Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. J Clin Lipidol. In press, 2025. doi:10.1016\/j.jacl.2024.09.008.","DOI":"10.1016\/j.jacl.2024.09.008"},{"key":"10.1016\/j.ajpc.2025.100978_bib0019","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ecl.2022.02.010","article-title":"Hypertriglyceridemia","volume":"51","author":"Chait","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"10.1016\/j.ajpc.2025.100978_bib0021","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2018.06.042","article-title":"Familial chylomicronemia syndrome","volume":"72","author":"Shah","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100978_bib0022","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199609193351203","article-title":"Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene","volume":"335","author":"Benlian","year":"1996","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0023","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/HCO.0000000000000839","article-title":"Genetics of hypertriglyceridemia and atherosclerosis","volume":"36","author":"Gill","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ajpc.2025.100978_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.886266","article-title":"The evolving story of multifactorial chylomicronemia syndrome","volume":"9","author":"Paquette","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100978_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacl.2010.11.004","article-title":"Etiology and risk of lactescent plasma and severe hypertriglyceridemia","volume":"5","author":"Tremblay","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100978_bib0026","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/ATVBAHA.122.318445","article-title":"Genetic testing for hypertriglyceridemia in academic lipid clinics: implications for precision medicine\u2014Brief report","volume":"42","author":"Deshotels","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"47","key":"10.1016\/j.ajpc.2025.100978_bib0027","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014A consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2025.100978_bib0028","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/j.jacl.2024.04.062","article-title":"Development of a clinical diagnostic score for familial chylomicronemia syndrome (FCS) [abstract]","volume":"18","author":"Campos","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2025.100978_bib0029","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clinbiochem.2023.02.002","article-title":"Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity","volume":"114","author":"Brisson","year":"2023","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100978_bib0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/MED.0000000000000846","article-title":"Multifactorial chylomicronemia syndrome","volume":"31","author":"Chait","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ajpc.2025.100978_bib0031","doi-asserted-by":"crossref","unstructured":"Spagnuolo CM, Wang J, McIntyre AD, Kennedy BA, Hegele RA Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome. J Clin Endocrinol Metab. In press, 2025. doi:10.1210\/clinem\/dgae613.","DOI":"10.1016\/j.jcjd.2024.09.046"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100978_bib0032","doi-asserted-by":"crossref","first-page":"883","DOI":"10.5551\/jat.RV17054","article-title":"Current diagnosis and management of primary chylomicronemia","volume":"28","author":"Okazaki","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ajpc.2025.100978_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2025.110873","article-title":"DNA methylation levels may contribute to severe hypertriglyceridemia in multifactorial chylomicronemia syndrome","volume":"135","author":"Guay","year":"2025","journal-title":"Clin Biochem"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100978_bib0034","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100978_bib0035","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/jcm10040669","article-title":"Non-alcoholic fatty liver in patients with chylomicronemia","volume":"10","author":"Maltais","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100978_bib0036","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40265-022-01766-4","article-title":"Acute pancreatitis: diagnosis and treatment","volume":"82","author":"Szatmary","year":"2022","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ajpc.2025.100978_bib0037","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinchem\/hvad094","article-title":"Hypertriglyceridemia-associated pancreatitis: new concepts and potential mechanisms","volume":"69","author":"Hansen","year":"2023","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0038","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02803766","article-title":"Role of hypertriglyceridemia in the pathogenesis of experimental acute pancreatitis in rats","volume":"20","author":"Kimura","year":"1996","journal-title":"Int J Gastrointest Cancer"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13916","article-title":"Mechanisms linking hypertriglyceridemia to acute pancreatitis","volume":"237","author":"Kiss","year":"2023","journal-title":"Acta Physiol"},{"key":"10.1016\/j.ajpc.2025.100978_bib0040","first-page":"117","article-title":"Pathogenesis, differentiation and management of hyperglyceridemia","volume":"15","author":"Havel","year":"1969","journal-title":"Adv Intern Med"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100978_bib0041","first-page":"60","article-title":"Acute pancreatitis with hyperlipemia: studies with an isolated perfused canine pancreas","volume":"82","author":"Saharia","year":"1977","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100978_bib0042","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3111\/13696998.2013.779277","article-title":"Medical resource use and costs associated with chylomicronemia","volume":"16","author":"Gaudet","year":"2013","journal-title":"J Med Econ"},{"issue":"10","key":"10.1016\/j.ajpc.2025.100978_bib0043","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/ajg.2015.261","article-title":"Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis","volume":"110","author":"Nawaz","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100978_bib0044","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.atherosclerosis.2014.09.029","article-title":"Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels","volume":"237","author":"Toth","year":"2014","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100978_bib0045","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ajpc.2025.100978_bib0046","article-title":"Serum triglyceride levels are associated with recurrence in patients with acute hypertriglyceridemic pancreatitis","volume":"10","author":"Guan","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100978_bib0047","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41525-021-00190-z","article-title":"Genetic basis of hypercholesterolemia in adults","volume":"6","author":"Saadatagah","year":"2021","journal-title":"NPJ Genomic Med"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100978_bib0048","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1038\/s41467-020-17374-3","article-title":"Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions","volume":"11","author":"Fahed","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100978_bib0049","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jacl.2023.08.003","article-title":"Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants","volume":"17","author":"Perera","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100978_bib0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0021-9150(77)90141-1","article-title":"Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia","volume":"26","author":"Beaumont","year":"1977","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100978_bib0051","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1210\/jc.2005-0205","article-title":"Combination of circulating antilipoprotein lipase (anti-LPL) antibody and heterozygous S172 fsX179 mutation of LPL gene leading to chronic hyperchylomicronemia","volume":"90","author":"Pruneta-Deloche","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ajpc.2025.100978_bib0052","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1194\/jlr.R120001116","article-title":"Chylomicronemia from GPIHBP1 autoantibodies","volume":"61","author":"Miyashita","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ajpc.2025.100978_bib0053","first-page":"407","article-title":"A systematic review and meta-analysis of observational studies on the effects of epigenetic factors on serum triglycerides","volume":"66","author":"Mazaheri-Tehrani","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0054","first-page":"408","article-title":"Screening program for familial hyperchylomicronemia syndrome detection: experience of a university health system","volume":"67","author":"Masson","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.ajpc.2025.100978_bib0055","article-title":"The right to be screened: identifying and addressing inequities in genetic screening","volume":"11","author":"Swami","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100978_bib0056","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/GIM.0b013e3181ab22aa","article-title":"Barriers to the use of genetic testing: a study of racial and ethnic disparities","volume":"11","author":"Suther","year":"2009","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.ajpc.2025.100978_bib0057","article-title":"New case detection by cascade testing in familial hypercholesterolemia","volume":"12","author":"Lee","year":"2019","journal-title":"Circ Genomic Precis Med"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100978_bib0058","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.gim.2022.08.026","article-title":"A pragmatic clinical trial of cascade testing for familial hypercholesterolemia","volume":"24","author":"Miller","year":"2022","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0059","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/08998280.2018.1463784","article-title":"Identifying suspected familial chylomicronemia syndrome","volume":"31","author":"Rengarajan","year":"2018","journal-title":"Proc Bayl Univ Med Cent"},{"issue":"19","key":"10.1016\/j.ajpc.2025.100978_bib0060","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100978_bib0061","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.100978_bib0062","unstructured":"United States. Congress. H.R.4013\u2014107th Congress (2001-2002): Rare Diseases Act of 2002. Available at: https:\/\/www.congress.gov\/bill\/107th-congress\/house-bill\/4013. Accessed 20 February 2025."},{"issue":"4","key":"10.1016\/j.ajpc.2025.100978_bib0063","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.ajpc.2025.100978_bib0064","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/0026-0495(92)90293-J","article-title":"Treatment of primary chylomicronemia due to familial hypertriglyceridemia by \u03c9-3 fatty acids","volume":"41","author":"Richter","year":"1992","journal-title":"Metabolism"},{"issue":"20","key":"10.1016\/j.ajpc.2025.100978_bib0065","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJM197911153012001","article-title":"Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis","volume":"301","author":"Goldberg","year":"1979","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0066","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1194\/jlr.M200282-JLR200","article-title":"Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance","volume":"44","author":"Park","year":"2003","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0067","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100978_bib0068","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100978_bib0069","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jama.1991.03460070086049","article-title":"The familial hyperchylomicronemia syndrome. New insights into underlying genetic defects","volume":"265","author":"Santamarina-Fojo","year":"1991","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100978_bib0070","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/FPC.0b013e328340095e","article-title":"Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics","volume":"20","author":"Brisson","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100978_bib0071","first-page":"93","article-title":"The use of orlistat in an adult with lipoprotein lipase deficiency: a case report","volume":"8","author":"Jarrett","year":"2022","journal-title":"AACE Clin Case Rep"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100978_bib0072","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1210\/jc.2018-00369","article-title":"Orlistat therapy for children with type 1 hyperlipoproteinemia: a randomized clinical trial","volume":"103","author":"Patni","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"8A","key":"10.1016\/j.ajpc.2025.100978_bib0073","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100978_bib0074","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11883-022-00982-3","article-title":"The effect of GLP-1 receptor agonists on postprandial lipaemia","volume":"24","author":"Novodvorsk\u00fd","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100978_bib0075","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/dom.14174","article-title":"The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes","volume":"22","author":"Wilson","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajpc.2025.100978_bib0076","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"23","key":"10.1016\/j.ajpc.2025.100978_bib0077","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.100978_bib0078","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of apoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100978_bib0079","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100978_bib0080","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.ajpc.2025.100978_bib0081","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100978_bib0082","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacl.2009.09.003","article-title":"Efficacy and tolerability of multidrug therapy for hypertriglyceridemia","volume":"3","author":"Polsani","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.ajpc.2025.100978_bib0083","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ajpc.2025.100978_bib0084","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100978_bib0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.ajpc.2025.100978_bib0086","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100978_bib0087","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100978_bib0088","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"issue":"40","key":"10.1016\/j.ajpc.2025.100978_bib0089","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100978_bib0090","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ajpc.2025.100978_bib0091","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100978_bib0092","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpc.2025.100978_bib0093","series-title":"Crossing the quality chasm: a new health system for the 21st century","year":"2001"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:06:13Z","timestamp":1762639573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667725000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":93,"alternative-id":["S2666667725000509"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.100978","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.100978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc on behalf of National Lipid Association and Elsevier BV.","name":"copyright","label":"Copyright"}],"article-number":"100978"}}